Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys

Behavioural Pharmacology

Volumn 16, Issue 1, 2005, Pages 53-58

  Sell, S L ^a,b   McMahon, L R ^b   Koek, W ^b,c   France, Charles P ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Dependence; LAAM; Monoamines; Naltrexone; Opioid; Rhesus monkey; Withdrawal

Indexed keywords

AMPHETAMINE; CLONIDINE; COCAINE; DOPAMINE; HALOPERIDOL; IMIPRAMINE; LEVACETYLMETHADOL; LIGAND; MONOAMINE; NALTREXONE; NORADRENALIN; OPIATE;

ABDOMINAL RIGIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BREATHING; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; LIGAND BINDING; MALE; MONKEY; MONOAMINERGIC SYSTEM; NONHUMAN; RHESUS MONKEY; RIGIDITY; SALIVATION DISORDER;

ADRENERGIC ALPHA-AGONISTS; AMPHETAMINE; ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOGENIC MONOAMINES; CLONIDINE; COCAINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; IMIPRAMINE; MACACA MULATTA; MALE; METHADYL ACETATE; MUSCLE RIGIDITY; NALTREXONE; NARCOTIC ANTAGONISTS; RESPIRATORY MECHANICS; SALIVATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 14844362510     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200502000-00006     Document Type: Article

References (25)

1. Brandt MR, France CP (1998). Chronic L-alpha acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal. J Pharmacol Exp Ther 287:1029-1037.
2. France CP, Woods JH (1989). Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250: 937-943.
3. Freud S (1887). Craving for and fear of cocaine. In: Byck R (editor): Cocaine Papers. New York: Stonehill; pp. 171-176.
4. Gellert VF, Holtzman SG (1979). Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther 211:596-605.
5. Gonzalez G, Oliveto A, Kosten TR (2004). Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 5:713-725.
6. Gray AM (2002). The effect of fluvoxamine and sertraline on the opioid withdrawal syndrome: a combined in vivo cerebral microdialysis and behavioural study. Eur Neuropsychopharmacol 12:245-254.
7. Herz A, Blasig J, Papeschi R (1974). Role of catecholaminergic mechanisms in the expression of the morphine abstinence syndrome in rats. Psychopharmacologia 39:121-143.
8. Hunt DE, Lipton DS, Goldsmith D, Strug D (1984). Street pharmacology: uses of cocaine and heroin in the treatment of addiction. Drug Alcohol Depend 13:375-387.
9. Institute of Laboratory Animal Resources on Life Sciences (1996). Guide for the Care and Use of Laboratory Animals. National Research Council Publication No. (NIH) 85-23, revised. Washington DC: Department of Health, Education and Welfare.
10. Jasinski DR, Johnson RE, Kocher TR (1985). Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42: 1063-1066.
11. Katz JL (1986). Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys. Psychopharmacology (Berl) 88:392-397.
12. Koob GF, Wall TL, Bloom FE (1989). Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology (Berl) 98:530-534.
13. Kosten TA (1990). Cocaine attenuates the severity of naloxone- precipitated opioid withdrawal. Life Sci 47:1617-1623.
14. Kosten TA, Kosten TR (1989). Cocaine abuse and opioid withdrawal. Lancet 15:165-166.
15. Kreek MJ (2000). Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186-216.
16. Maldonado R (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 21:91-104.
17. Maruyama Y, Takemori AE (1973). The role of dopamine and norepinephrine in the naloxone-induced abstinence of morphine-dependent mice. J Pharmacol Exp Ther 185:602-608.
18. Matsuzaki M, Spingler PJ, Whitlock EG, Misra AL, Mule SJ (1978). Comparative effects of cocaine and pseudococaine on EEG activities, cardiorespiratory functions, and self-administration behavior in the rhesus monkey. Psychopharmacology (Berl) 57:13-20.
19. McMahon LR, Sell SL, France CP (2004). Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 308:111-119.
20. Paronis CA, Woods JH (1997). Ventilation in morphine-maintained rhesus monkeys. I: Effects of naltrexone and abstinence-associated withdrawal. J Pharmacol Exp Ther 282:348-354.
21. Rosen MI, Wallace EA, Sullivan MC, Stine S, Kosten TR (1992). Use of cocaine to prevent opiate withdrawal. Am J Psychiatry 149:1609.
22. Rossetti ZL, Hmaidan Y, Gessa GL (1992). Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221:227-234.
23. Rowlett JK, Platt DM, Spealman RD (2004). Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors. J Pharmacol Exp Ther 310:342-348.
24. Sell SL, France CP (2002). Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. J Pharmacol Exp Ther 301:1103-1110.
25. Stine SM, Kosten TR (1994). Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. Am J Drug Alcohol Abuse 20:445-458.